Vanguard Group Inc. Acquires 134,283 Shares of Akebia Therapeutics, Inc. (AKBA)

Vanguard Group Inc. raised its holdings in Akebia Therapeutics, Inc. (NASDAQ:AKBA) by 10.3% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,436,163 shares of the biopharmaceutical company’s stock after purchasing an additional 134,283 shares during the period. Vanguard Group Inc. owned approximately 7.85% of Akebia Therapeutics worth $20,638,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Creative Planning boosted its holdings in Akebia Therapeutics by 2.9% in the 2nd quarter. Creative Planning now owns 10,650 shares of the biopharmaceutical company’s stock valued at $153,000 after purchasing an additional 300 shares during the period. Rhumbline Advisers boosted its holdings in Akebia Therapeutics by 1.3% in the 2nd quarter. Rhumbline Advisers now owns 41,510 shares of the biopharmaceutical company’s stock valued at $596,000 after purchasing an additional 518 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Akebia Therapeutics by 1.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 49,277 shares of the biopharmaceutical company’s stock valued at $453,000 after purchasing an additional 608 shares during the period. Legal & General Group Plc boosted its holdings in Akebia Therapeutics by 8.0% in the 2nd quarter. Legal & General Group Plc now owns 9,672 shares of the biopharmaceutical company’s stock valued at $142,000 after purchasing an additional 714 shares during the period. Finally, Wells Fargo & Company MN boosted its holdings in Akebia Therapeutics by 1.0% in the 2nd quarter. Wells Fargo & Company MN now owns 88,116 shares of the biopharmaceutical company’s stock valued at $1,266,000 after purchasing an additional 880 shares during the period. 59.27% of the stock is owned by hedge funds and other institutional investors.

Shares of Akebia Therapeutics, Inc. (NASDAQ AKBA) opened at $14.24 on Wednesday. Akebia Therapeutics, Inc. has a twelve month low of $7.78 and a twelve month high of $20.25.

Akebia Therapeutics (NASDAQ:AKBA) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.56) by $0.07. Akebia Therapeutics had a negative net margin of 137.80% and a negative return on equity of 198.85%. The company had revenue of $41.28 million during the quarter, compared to the consensus estimate of $34.00 million. equities analysts predict that Akebia Therapeutics, Inc. will post -2.74 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Vanguard Group Inc. Acquires 134,283 Shares of Akebia Therapeutics, Inc. (AKBA)” was first published by Week Herald and is owned by of Week Herald. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://weekherald.com/2017/11/15/vanguard-group-inc-acquires-134283-shares-of-akebia-therapeutics-inc-akba.html.

A number of research firms have issued reports on AKBA. Zacks Investment Research raised shares of Akebia Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 price objective for the company in a report on Monday. Mizuho reaffirmed a “buy” rating and set a $24.00 price target on shares of Akebia Therapeutics in a report on Thursday, November 9th. Royal Bank Of Canada reaffirmed a “hold” rating and set a $17.00 price target on shares of Akebia Therapeutics in a report on Thursday, November 2nd. ValuEngine raised shares of Akebia Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Finally, BidaskClub raised shares of Akebia Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 16th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $20.75.

In related news, SVP Michel Dahan sold 1,398 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $19.64, for a total transaction of $27,456.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In the last ninety days, insiders have sold 7,586 shares of company stock valued at $147,289. 8.67% of the stock is currently owned by insiders.

About Akebia Therapeutics

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Want to see what other hedge funds are holding AKBA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Akebia Therapeutics, Inc. (NASDAQ:AKBA).

Institutional Ownership by Quarter for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply